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regression and the Area Under the Receiver Operating Curve 
(Az)). 
Results: Of three distinct symptom groups identified in all 
cohorts, labelled Erectile dysfunction (ED), Orgasm 
dysfunction, and Pain, dose to CC, PB, and CC+PB was 
associated (p≤0.05) with symptoms in ED. For the EBRT 
cohort, prediction of any ED symptom/symptoms was the 
highest with CC Dmax (Az=0.83; p=0.002). Weaker, but still 
significant, relationships were found also with CC+PB and PB 
Dmax, as well as with CC+PB Dmean (Az=0.72-0.74; p=0.02-0.04). 
For the POSTOP cohort, CC and CC+PB Dmean predicted one ED 
symptom (Az=0.65-0.66; 0.02-0.03).  
Conclusions: Based on patient-reported symptoms on sexual 
dysfunction from two cohorts, our results suggest that dose 
to the corpora cavernosa, alone or in combination with the 
penile bulb may be critical for erectile dysfunction following 
EBRT for localized prostate cancer. By uncovering the 
interactions between symptoms as well as how they can be 
explained by dose to the investigated structures, our findings 
have the potential to contribute to a better understanding of 
the underlying radiation-induced causes for sexual 
dysfunction.  
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Purpose/Objective: Preoperative chemoradiotherapy for 
rectal cancer reduces the risk of local recurrence, but also 
induces gastrointestinal (GI) toxicity. Acute GI toxicity might, 
in addition to the discomfort caused to patients, threaten 
treatment compliance. Modern radiotherapy techniques, such 
as intensity modulated radiotherapy (IMRT), can reduce dose 
delivered to the bowel, potentially limiting acute GI toxicity. 
Previous studies have reported dose-volume relationships for 
acute GI toxicity for patients treated with 3D conformal 
techniques (3D-CRT), but few have examined patients 
treated with IMRT. 
Materials and Methods: We explored dose metrics 
correlating with acute diarrhea and chemotherapy 
compliance for a single-institution cohort of rectal cancer 
patients (n=115) treated with IMRT. Acute diarrhea during 
treatment was scored prospectively by trained RT nurses 
(CTCAE v3.0). The highest toxicity score was used for 
analysis. Treatment charts were retrospectively reviewed for 
chemotherapy compliance; defined as no treatment 
interruptions, discontinuations, or dose reductions. The 
entire intestinal cavity containing small bowel loops up to the 
upper level of L5 was delineated by experienced radiation 
oncologists. IMRT treatment planning used a 5- or 7-field 
technique with 6 MV photon beams. Most patients were given 
60 Gy in 30 fractions to the tumour and 50 Gy in 30 fractions 
to lymph node targets, and many received an additional 
tumour boost (either external beam or brachytherapy). 
Ordinal and binary logistic modelling was used to correlate 
absolute volumes of intestinal cavity receiving x Gy or above 
(Vx) to graded toxicity scores and chemotherapy treatment 
compliance. Optimal value of the dose cut-off x was chosen 
by maximum likelihood technique accounting for scanning the 
cut-point. Clinical factors (see Table 1) were included one by 
one in both models to examine their association with 




Results: V32Gy correlated with acute diarrhea (p=0.0001), see 
Fig 1a; females had an increased risk of toxicity (OR=2.13, 
95% CI 1.03–4.42, p=0.04). V46Gy correlated with 
chemotherapy compliance (p=0.005, 100 patients receiving 
concurrent chemotherapy), see Fig 1b. Women had lower 
treatment compliance (OR=2.41, 1.09–5.34, p=0.03), as had 
patients with low BMI (OR=0.89, 0.80–0.99, for 1 point 
increase in BMI, p=0.03) and patients with diabetes (OR=7.29, 
1.21–43.8, p=0.03). Age, brachytherapy boost, prior 
abdominal surgery, smoking history, or domestic status had 
no influence on any of the two endpoints, nor had concurrent 
chemotherapy on the risk of acute diarrhea. 





Conclusions: We found that dose to the intestinal cavity 
(V32Gy and V46Gy) was associated with acute diarrhea and 
chemotherapy treatment compliance in patients treated with 
IMRT for primary rectal cancer. The results are not in direct 
agreement with results from patient cohorts treated with 3D-
CRT, where V15Gy has consistently been reported as an 
optimal dose cut-off. 
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Purpose/Objective: Opinion in the literature is divided as to 
whether the LQ model of cell kill, and consequently TCP 
models based on it, are applicable for the relatively high 
dose per fraction delivered during SABR treatments of NSCLC. 
This work aimed to establish whether LQ-based TCP 
modelling can adequately describe observed local control in 
NSCLC radiotherapy for both 3D-CRT and SABR deliveries, 
through fitting model parameters to reported outcomes for 
both techniques. 
Materials and Methods: Two patient cohorts, each 
comprising approximately 25 clinical PTV DVHs, were 
constructed from retrospective clinical data for mixed-stage 
3D-CRT and stage I SABR treatments. Cohorts differed in GTV 
sizes (averaging 106 cm3 for 3D-CRT and 15 cm3 for SABR) and 
dose variation due to the lower isodose level (67 to 80% of 
isocentre dose) covering the PTV for SABR. An LQ-based TCP 
model was used to predict local control for individual PTV 
DVHs, which were then averaged over each cohort to 
estimate local control for that population. Fixed parameters 
were clonogen density within the GTV (1e7 cm-3), alpha-beta 
ratio (10 Gy), time to the onset of accelerated repopulation, 
Tk (21 days) and doubling time, Td (3.7 days). Free 
parameters fitted to published outcome data were mean 
radiosensitivity, α, and standard deviation σα. Parameters 
were fitted to reported local control at 2 years for a range of 
dose/fractionation schedules using maximum likelihood 
estimation. Best fit parameters were derived for combined 
3D-CRT and SABR outcome data and for each technique 
separately. Uncertainty estimates on derived parameter 
values were derived from likelihood profiles to assess the 
significance of parameter set differences. 
Results: Best-fit TCP model parameters (and 95% confidence 
intervals) for combined 3D-CRT and SABR cohorts were α = 
0.293 (0.286 to 0.302) Gy-1 and σα = 0.051 (0.042 to 0.067). 
Best-fit parameters resulting from separate fitting to only 3D-
CRT data fell within the 95% confidence limits of these 
values. For SABR-only fitting, α (only) fell outside this 
confidence interval; α = 0.313, σα = 0.06, however the 95% 
confidence interval on SABR-derived α (0.292 to 0.342) 
encompassed the fit to combined data. Resulting local 
control estimates are compared with the literature in the 
figure below, along with the predictions for separate model 
fitting to 3D-CRT and to SABR data. Repopulation-corrected 
equivalent 2Gy dose (EQD2) to the isocentre is used as the 
metric, indicating a smooth transition from 3D-CRT to SABR 
techniques. 
 
Conclusions: An LQ-based TCP model was found to 
adequately reproduce reported 2-year local control for both 
3D-CRT and SABR NSCLC techniques. Further, a common 
parameter set (α, σα) was found to be consistent with data 
for both techniques, despite the large dose and GTV size 
differences between patient cohorts. No significant 
advantage was found in fitting parameters to each technique 
separately.  
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